Project Grant R01CA305965
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $704K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- The National Cancer Institute awarded The Trustees of The University of Pennsylvania $703,071 on April 10, 2026, under the Cancer Treatment Research program (CFDA 93.395) to define the determinants of long-term CAR-T cell persistence in blood cancer patients. The research identifies the cellular and molecular properties of CAR-T cells that sustain durable anti-tumor function years after infusion. Prior work by the investigative team revealed that long-lived CAR-T cells up to five years...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded The Trustees of The University of Pennsylvania $668,864 on June 15, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award funds development of a biomarker to predict patient response to chimeric antigen receptor (CAR) T cell therapy for glioblastoma and to identify mechanisms of tumor resistance to CAR T treatment. The research employs...
- The National Cancer Institute awarded $164,190 to the University of Pennsylvania on January 15, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support identification of genes that limit CAR T persistence in solid tumors. Work runs through July 31, 2029, and is performed in Philadelphia, Pennsylvania. The project conducts genome-wide in vivo CRISPR screening of human CAR T cell persistence in solid tumor microenvironments. Prior work identified USP22 and ATXN7L3—components of...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded The Trustees of The University of Pennsylvania $1.376 million on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) for Project Grant R01CA303022. The award funds development of optimized invariant natural killer T (iNKT) cell therapies engineered with chimeric antigen receptors (CARs) to treat solid tumors. The project pairs high-performing iNKT cell...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia $738,666 on August 4, 2026, under the Cancer Treatment Research program (CFDA 93.395) to engineer CD19 mimotopes for enhancing and repurposing CD19-CAR T cell therapy against hematological malignancies and solid tumors. The recipient will develop a high-affinity CD19 mimotope identified through yeast surface display screening to pair with existing CD19-CAR T products. The linear mimotope, a 10 amino acid peptide, is...
- The National Cancer Institute awarded The Trustees of The University of Pennsylvania $147,874 on August 13, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research into the mechanisms of enhancer regulation by EBF1 in mantle cell lymphoma. The research will uncover how EBF1 influences three-dimensional genome organization in mantle cell lymphoma, a highly aggressive B-cell malignancy. The investigator will employ super-resolution microscopy and long-read sequencing...
- The Food and Drug Administration awarded The Trustees of the University of Pennsylvania $6.843 million on September 30, 2025, under the Food and Drug Administration Research program (CFDA 93.103) to conduct a first-in-human Phase I clinical trial evaluating CD5-deleted chimeric antigen receptor T cells (SENZA5 CAR-T5) for the treatment of relapsed or refractory T-cell non-Hodgkin lymphoma. The trial will assess the feasibility, toxicity, and efficacy of this novel immunotherapy approach, which...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia $737,082 on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop bioinspired virus-like nanovaccines that boost chimeric antigen receptor (CAR) T cell and endogenous T cell responses against solid tumors with antigen heterogeneity. The recipient will develop an autologous tumor cell membrane-coated dual CAR and endogenous T cell boosting virus-like nanoparticle vaccine (DTVLP-VAX) to...
- The National Cancer Institute awarded the Regents of the University of Michigan $401,115 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate novel therapeutic strategies targeting the enhancer landscape in high-risk T-cell lymphomas. The research addresses T-cell lymphomas driven by the transcription factor GATA-3, which remain largely incurable with existing therapies. The project characterizes GATA-3-dependent enhancers and evaluates P300/CBP bromodomain...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded The Trustees of The University of Pennsylvania $618,063 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop FLASH-CAR-T radioimmunotherapy for pediatric brain tumors. The project aims to advance immunomodulatory therapy for pediatric brain malignancies including medulloblastoma and glioma by combining FLASH proton beam radiation with...